| 1 |
ICV228 |
19.36 | 62.71% | 30.88% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=2µM) |
| 2 |
ICV229 |
18.96 | 61.76% | 30.69% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=0.7µM) |
| 3 |
ICV233 |
18.91 | 61.68% | 30.66% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=2.1µM) |
| 4 |
ICV230 |
18.75 | 60.84% | 30.82% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=0.97µM) |
| 5 |
ICV198 |
18.17 | 61.26% | 29.66% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=58.35µM) |
| 6 |
ICV231 |
17.93 | 58.79% | 30.5% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=0.051µM) |
| 7 |
ICV436 |
17.82 | 54.49% | 32.7% |
human: MEK1,2 | NA | NA |
| 8 |
ICV219 |
17.81 | 60.14% | 29.61% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=9.1µM) |
| 9 |
ICV236 |
17.69 | 57.33% | 30.85% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=8.1µM) |
| 10 |
ICV235 |
17.64 | 57.58% | 30.63% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=22.1µM) |
| 11 |
ICV237 |
17.35 | 56.5% | 30.71% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=4.1µM) |
| 12 |
ICV225 |
17.21 | 59.02% | 29.17% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=25.3µM) |
| 13 |
ICV221 |
17.2 | 57.84% | 29.74% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=3.8µM) |
| 14 |
ICV222 |
17.07 | 58.77% | 29.04% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=22.5µM) |
| 15 |
ICV223 |
16.91 | 58.24% | 29.04% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=4.1µM) |
| 16 |
ICV226 |
16.9 | 57.81% | 29.24% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=7.72µM) |
| 17 |
ICV232 |
16.86 | 53.69% | 31.41% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=1.5µM) |
| 18 |
ICV124 |
16.82 | 58.07% | 28.97% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(Ki=0.68µM) |
| 19 |
ICV431 |
16.82 | 55.84% | 30.11% |
human: Histamine H1 receptor | P35367 | MERS(EC50=4.884µM) Vero E6; SARS(EC50=5.591µM) Vero E6 |
| 20 |
ICV202 |
16.63 | 53.74% | 30.95% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=90.72µM) |
